<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM13209</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-13209</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Studies</subject></subj-group></article-categories><title-group><article-title>Избыточная масса тела и ожирение у больных сахарным диабетом 1 типа: ассоциации с сосудистыми осложнениями и биомаркерами сосудистого ремоделирования</article-title><trans-title-group xml:lang="en"><trans-title>Overweight and obesity in patients with type 1 diabetes: associations with vascular complications and biomarkers of vascular remodeling</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5407-8722</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Климонтов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Klimontov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Климонтов Вадим Валерьевич - д.м.н., профессор; Researcher ID: R-7689-2017; Scopus Author ID: 8295977000.</p><p>630060, Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Vadim V. Klimontov - MD, PhD, Professor; Researcher ID: R-7689-2017; Scopus Author ID: 8295977000</p><p>2 Timakov street, 630060 Novosibirsk</p></bio><email xlink:type="simple">klimontov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-6565-7466</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юшин</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Yushin</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юшин Антон Юрьевич - м.н.с.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Аnton Yu. Yushin, MD, junior researcher.</p><p>Novosibirsk</p></bio><email xlink:type="simple">antyush@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3118-0406</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семёнова</surname><given-names>Ю. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Semenova</surname><given-names>Yu. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Семёнова Юлия Федоровна - к.м.н., н.с.; Scopus Author ID: 55522435000.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Julia F. Semenova - MD, PhD, researcher; Scopus Author ID: 55522435000.</p><p>Novosibirsk</p></bio><email xlink:type="simple">ekmxtyjr@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3502-5892</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корбут</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Korbut</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Корбут Антон Иванович - к.м.н., ст.н.с.; Scopus Author ID: 57151138800.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Anton I. Korbut - MD, PhD, senior research associate; Scopus Author ID: 57151138800.</p><p>Novosibirsk</p></bio><email xlink:type="simple">anton.korbut@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1953-2536</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Романов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Romanov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Романов Вячеслав Витальевич - к.м.н., н.с.; Scopus Author ID: 56810492000.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Vyacheslav V. Romanov - MD, PhD, researcher; Scopus Author ID: 56810492000.</p><p>Novosibirsk</p></bio><email xlink:type="simple">slavrom@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт клинической и экспериментальной лимфологии — филиал ФГБНУ Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Clinical and Experimental Lymphology – branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>18</day><month>01</month><year>2025</year></pub-date><volume>27</volume><issue>6</issue><fpage>528</fpage><lpage>535</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Климонтов В.В., Юшин А.Ю., Семёнова Ю.Ф., Корбут А.И., Романов В.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Климонтов В.В., Юшин А.Ю., Семёнова Ю.Ф., Корбут А.И., Романов В.В.</copyright-holder><copyright-holder xml:lang="en">Klimontov V.V., Yushin A.Y., Semenova Y.F., Korbut A.I., Romanov V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/13209">https://www.dia-endojournals.ru/jour/article/view/13209</self-uri><abstract><sec><title>ОБОСНОВАНИЕ</title><p>ОБОСНОВАНИЕ. Распространенность избыточной массы тела и ожирения у больных сахарным диабетом 1 типа (СД1) увеличивается, что актуализирует вопрос об их влиянии на развитие осложнений.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Изучить ассоциации избыточной массы тела и ожирения с сосудистыми осложнениями, факторами сердечно-сосудистого риска и уровнем биомаркеров сосудистого ремоделирования в сыворотке крови у больных СД1.</p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ. В исследование включено 547 больных СД1, в том числе 309 с индексом массы тела (ИМТ) &lt;25 кг/м², 155 — с ИМТ 25–29,9 кг/м² и 83 человека с ИМТ ≥30 кг/м². Чувствительность к инсулину оценивали на основании расчетной скорости утилизации глюкозы. В сыворотке крови у 130 пациентов и 30 лиц с нормальной массой тела и нормальной толерантностью к глюкозе (контроль) определяли концентрации поздних продуктов гликирования (AGEs), эндотелина-1, эндотелиальной NO-синтазы (NOS3), адреномедуллина (ADM), молекулы, специфичной для эндотелиальных клеток-1 (ESM1), молекул клеточной адгезии (ICAM-1 и VCAM-1), интегрин-ассоциированного протеина-1 (IAP-1), субъединицы интегринового рецептора (ITGB1), гемоксигеназы-1 (HO-1), белка GAS6, декорина, трансформирующего фактора роста β1 (TGF-β1) с помощью ИФА.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Ожирение у больных СД1 было независимо ассоциировано с ишемической болезнью сердца (ИБС), инфарктом миокарда и хронической сердечной недостаточностью (ХСН). Избыточная масса тела оказалась независимым предиктором ХСН. Лица с ИМТ≥25 кг/м² при сравнении с пациентами с ИМТ&lt;25 кг/м², были старше, имели сниженную чувствительность к инсулину, более высокие уровни триглицеридов, холестерина, липопротеидов низкой плотности (ЛПНП), мочевой кислоты и высокочувствительного С-реактивного белка. У больных СД1 в сравнении с контролем выявлено значимое повышение уровня в сыворотке крови AGEs, эндотелина-1, ICAM-1, VCAM-1, IAP-1, ESM1, HO-1, GAS6 и TGF-β1. Пациенты с избыточной массой тела при сравнении с больными с ИМТ&lt;25 кг/м² демонстрировали более высокие уровни ICAM-1, IAP-1, ITGB1 и TGF-β1, а у больных с ожирением были повышены концентрации AGEs, IAP-1 и HO-1.</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. У больных СД1 избыточная масса тела и ожирение ассоциированы с сосудистыми осложнениями, факторами их риска и биомаркерами сосудистого ремоделирования.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: The prevalence of overweight and obesity in patients with type 1 diabetes (T1D) is increasing, which raises the issue of their impact on the development of complications.</p></sec><sec><title>AIM</title><p>AIM: to study the associations of overweight and obesity with vascular complications, cardiovascular risk factors and serum levels of vascular remodeling biomarkers in patients with T1D.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: The study included 547 patients, including 309 with body mass index (BMI) &lt;25 kg/m2, 155 with BMI 25–29.9 kg/m2, and 83 with BMI ≥30 kg/m2. Insulin sensitivity was assessed by the estimated glucose disposal rate. In the serum of 130 patients and 30 individuals with normal weight and normal glucose tolerance, concentrations of advanced glycation end products (AGEs), endothelin-1, endothelial NO synthase (NOS3), adrenomedullin (ADM), endothelial cell-specific molecule-1 (ESM1), cell adhesion molecules (ICAM-1 and VCAM-1), integrin-associated protein-1 (IAP-1), integrin receptor subunit (ITGB1), heme oxygenase-1 (HO-1), GAS6, decorin, and transforming growth factor β1 (TGF-β1) were determined by ELISA.</p></sec><sec><title>RESULTS</title><p>RESULTS: Obesity in patients with T1D was independently associated with coronary artery disease, myocardial infarction, and chronic heart failure. Overweight was an independent predictor of chronic heart failure only. Patients with BMI ≥25 kg/m2, when compared with those with BMI &lt;25 kg/m2, were older, had a reduced insulin sensitivity and increased levels of triglycerides, LDL-cholesterol, uric acid, and high-sensitivity C-reactive protein. Patients with T1D, as compared with controls, showed a significant increase in serum AGEs, endothelin-1, ICAM-1, VCAM-1, IAP-1, ESM1, HO-1, GAS6, and TGF-β1. Overweight patients, when compared with those with BMI &lt;25 kg/m2, demonstrated higher levels of ICAM-1, IAP-1, ITGB1 and TGF-β1, while obese individuals had increased concentrations of AGEs, IAP-1 and HO-1.</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: In patients with T1D, overweight and obesity are associated with vascular complications, their risk factors and biomarkers of vascular remodeling.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 1 типа</kwd><kwd>ожирение</kwd><kwd>избыточная масса тела</kwd><kwd>диабетические осложнения</kwd><kwd>биомаркер</kwd><kwd>поздние продукты гликирования</kwd></kwd-group><kwd-group xml:lang="en"><kwd>type 1 diabetes</kwd><kwd>obesity</kwd><kwd>overweight</kwd><kwd>diabetic complications</kwd><kwd>biomarker</kwd><kwd>glycation end-products</kwd><kwd>advanced</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено за счет гранта Российского научного фонда (проект 20-15-00057-П)</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966. https://doi.org/10.1007/s00125-022-05787-2</mixed-citation><mixed-citation xml:lang="en">Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966. https://doi.org/10.1007/s00125-022-05787-2</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Schueren B, Ellis D, Faradji RN, et al. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 2021;9(11):776-785. https://doi.org/10.1016/S2213-8587(21)00246-1</mixed-citation><mixed-citation xml:lang="en">Van der Schueren B, Ellis D, Faradji RN, et al. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 2021;9(11):776-785. https://doi.org/10.1016/S2213-8587(21)00246-1</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kueh MTW, Chew NWS, Al-Ozairi E, le Roux CW. The emergence of obesity in type 1 diabetes. Int J Obes (Lond). 2024;48(3):289-301. https://doi.org/10.1038/s41366-023-01429-8</mixed-citation><mixed-citation xml:lang="en">Kueh MTW, Chew NWS, Al-Ozairi E, le Roux CW. The emergence of obesity in type 1 diabetes. Int J Obes (Lond). 2024;48(3):289-301. https://doi.org/10.1038/s41366-023-01429-8</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2021;13(1):25. https://doi.org/10.1186/s13098-021-00641-8</mixed-citation><mixed-citation xml:lang="en">Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2021;13(1):25. https://doi.org/10.1186/s13098-021-00641-8</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2015 Obesity Collaborators; Afshin A, Forouzanfar MH, Reitsma MB, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377(1):13-27. https://doi.org/10.1056/NEJMoa1614362</mixed-citation><mixed-citation xml:lang="en">GBD 2015 Obesity Collaborators; Afshin A, Forouzanfar MH, Reitsma MB, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377(1):13-27. https://doi.org/10.1056/NEJMoa1614362</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98-107. https://doi.org/10.1016/j.metabol.2018.10.011</mixed-citation><mixed-citation xml:lang="en">Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98-107. https://doi.org/10.1016/j.metabol.2018.10.011</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Мавлянова К.Р., Семёнова Ю.Ф., Орлов Н.Б., Климонтов В.В. Маркеры воспаления низкой интенсивности и уровни цитокинов в сыворотке крови у больных сахарным диабетом 1 типа: ассоциации со временем в диапазонах и вариабельностью уровня глюкозы // Сахарный диабет. — 2024. — Т. 27. — №3. — С. 214-223. https://doi.org/10.14341/DM13159</mixed-citation><mixed-citation xml:lang="en">Mavlyanova KR, Semenova JF, Orlov NB, Klimontov VV. Markers of chronic low-grade inflammation and serum cytokine levels in patients with type 1 diabetes: associations with time in ranges and glucose variability. Diabetes mellitus 2024;27(3):214-223. (In Russ.).. https://doi.org/10.14341/DM13159</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Сахарный диабет 1 типа у взрослых // Сахарный диабет. — 2020. — Т.23. — Прил. 1S. — С. 42-114. https://doi.org/10.14341/DM12505</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 1 in adults. Diabetes mellitus. 2020;23(1S):42-114. (In Russ.). https://doi.org/10.14341/DM12505</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Saik OV, Klimontov VV. Bioinformatic Reconstruction and Analysis of Gene Networks Related to Glucose Variability in Diabetes and Its Complications. Int J Mol Sci. 2020;21(22):8691. https://doi.org/10.3390/ijms21228691</mixed-citation><mixed-citation xml:lang="en">Saik OV, Klimontov VV. Bioinformatic Reconstruction and Analysis of Gene Networks Related to Glucose Variability in Diabetes and Its Complications. Int J Mol Sci. 2020;21(22):8691. https://doi.org/10.3390/ijms21228691</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Saik OV, Klimontov VV. Hypoglycemia, Vascular Disease and Cognitive Dysfunction in Diabetes: Insights from Text Mining-Based Reconstruction and Bioinformatics Analysis of the Gene Networks. Int J Mol Sci. 2021;22(22):12419. https://doi.org/10.3390/ijms222212419</mixed-citation><mixed-citation xml:lang="en">Saik OV, Klimontov VV. Hypoglycemia, Vascular Disease and Cognitive Dysfunction in Diabetes: Insights from Text Mining-Based Reconstruction and Bioinformatics Analysis of the Gene Networks. Int J Mol Sci. 2021;22(22):12419. https://doi.org/10.3390/ijms222212419</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Song J, Ma R, Yin L. Associations between estimated glucose disposal rate and arterial stiffness and mortality among US adults with non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2024;15:1398265. https://doi.org/10.3389/fendo.2024.1398265</mixed-citation><mixed-citation xml:lang="en">Song J, Ma R, Yin L. Associations between estimated glucose disposal rate and arterial stiffness and mortality among US adults with non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2024;15:1398265. https://doi.org/10.3389/fendo.2024.1398265</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Алфёрова В.И., Мустафина С.В. Распространенность ожирения во взрослой популяции Российской Федерации (обзор литературы) // Ожирение и метаболизм. — 2022. — Т.19. — №1. — С. 96-105. https://doi.org/10.14341/omet12809</mixed-citation><mixed-citation xml:lang="en">Alferova VI, Mustafina SV. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and metabolism. 2022;19(1):96-105. (In Russ.). https://doi.org/10.14341/omet12809</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72. https://doi.org/10.1089/dia.2018.0384</mixed-citation><mixed-citation xml:lang="en">Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72. https://doi.org/10.1089/dia.2018.0384</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Edqvist J, Rawshani A, Adiels M, et al. BMI, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes: Findings Against an Obesity Paradox. Diabetes Care. 2019;42(7):1297-1304. https://doi.org/10.2337/dc18-1446</mixed-citation><mixed-citation xml:lang="en">Edqvist J, Rawshani A, Adiels M, et al. BMI, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes: Findings Against an Obesity Paradox. Diabetes Care. 2019;42(7):1297-1304. https://doi.org/10.2337/dc18-1446</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Осложнения сахарного диабета: лечение и профилактика / Под ред. И.И. Дедова, М.В. Шестаковой. — М.: ООО «Издательство «Медицинское информационное агентство», 2017. — 744 с.</mixed-citation><mixed-citation xml:lang="en">Oslozhneniya saharnogo diabeta: lechenie i profilaktika. / Ed by Dedov I.I., Shestakova M.V. Moscow: Medicinskoe informacionnoe agentstvo; 2017. 744 p. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yang DR, Wang MY, Zhang CL, Wang Y. Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications. Front Endocrinol (Lausanne). 2024;15:1359255. https://doi.org/10.3389/fendo.2024.1359255</mixed-citation><mixed-citation xml:lang="en">Yang DR, Wang MY, Zhang CL, Wang Y. Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications. Front Endocrinol (Lausanne). 2024;15:1359255. https://doi.org/10.3389/fendo.2024.1359255</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Savulescu-Fiedler I, Mihalcea R, Dragosloveanu S, et al. The Interplay between Obesity and Inflammation. Life (Basel). 2024;14(7):856. https://doi.org/10.3390/life14070856</mixed-citation><mixed-citation xml:lang="en">Savulescu-Fiedler I, Mihalcea R, Dragosloveanu S, et al. The Interplay between Obesity and Inflammation. Life (Basel). 2024;14(7):856. https://doi.org/10.3390/life14070856</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou M, Zhang Y, Shi L, et al. Activation and modulation of the AGEs-RAGE axis: Implications for inflammatory pathologies and therapeutic interventions – A review. Pharmacol Res. 2024;206:107282. https://doi.org/10.1016/j.phrs.2024.107282</mixed-citation><mixed-citation xml:lang="en">Zhou M, Zhang Y, Shi L, et al. Activation and modulation of the AGEs-RAGE axis: Implications for inflammatory pathologies and therapeutic interventions – A review. Pharmacol Res. 2024;206:107282. https://doi.org/10.1016/j.phrs.2024.107282</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Sergi D, Boulestin H, Campbell FM, Williams LM. The Role of Dietary Advanced Glycation End Products in Metabolic Dysfunction. Mol Nutr Food Res. 2021;65(1):e1900934. https://doi.org/10.1002/mnfr.201900934</mixed-citation><mixed-citation xml:lang="en">Sergi D, Boulestin H, Campbell FM, Williams LM. The Role of Dietary Advanced Glycation End Products in Metabolic Dysfunction. Mol Nutr Food Res. 2021;65(1):e1900934. https://doi.org/10.1002/mnfr.201900934</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sohouli MH, Sharifi-Zahabi E, Lari A, et al. The impact of low advanced glycation end products diet on obesity and related hormones: a systematic review and meta-analysis. Sci Rep. 2020;10(1):22194. https://doi.org/10.1038/s41598-020-79216-y</mixed-citation><mixed-citation xml:lang="en">Sohouli MH, Sharifi-Zahabi E, Lari A, et al. The impact of low advanced glycation end products diet on obesity and related hormones: a systematic review and meta-analysis. Sci Rep. 2020;10(1):22194. doi: https://doi.org/10.1038/s41598-020-79216-y</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
